<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02398448</url>
  </required_header>
  <id_info>
    <org_study_id>ALLO-101(QCL116986)</org_study_id>
    <nct_id>NCT02398448</nct_id>
  </id_info>
  <brief_title>IVIVR Assessing PK Parameters Used to Establish Bioequivalence</brief_title>
  <official_title>In Vitro-In Vivo Relationship Study to Assess the Impact of the In Vitro Dissolution Profile on the Pharmacokinetic Parameters Used to Establish Bioequivalence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ardea Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Quotient Clinical</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ardea Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether defined and limited changes in in vitro&#xD;
      dissolution impact the in vivo pharmacokinetics (PK) and relative bioavailability of&#xD;
      allopurinol and the active metabolite oxypurinol.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, a single oral dose of Zyloprim® (300 mg tablet) and 3 separate single oral&#xD;
      doses of 300 mg allopurinol test formulations (Regimens B, C and D) will be administered&#xD;
      sequentially to each subject on separate occasions. Following the administration of Regimens&#xD;
      B and C, there will be a period of interim analysis during which the PK data will be reviewed&#xD;
      to determine the formulation within the process design space that provides the desired in&#xD;
      vitro dissolution variant for dosing in the subsequent study period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK profile of Zyloprim® and three dissolution test formulations of allopurinol from plasma</measure>
    <time_frame>Predose (within 30 minutes before dosing), 15, 30, and 45 minutes postdose, and 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, and 96 hours postdose.</time_frame>
    <description>PK endpoints in terms of maximum observed concentration (Cmax), time of occurrence of maximum observed concentration (Tmax), area under the concentration-time curve (AUClast), area under the concentration-time curve (AUC∞) and apparent terminal half-life (t1/2)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>11 weeks</time_frame>
    <description>Changes in Laboratory, Electrocardiogram and Vital Signs Parameters</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Zyloprim® 300 mg and three dissolution test formulations</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regimen A: Zyloprim® 300 mg; Regimen B: Allopurinol 300 mg; undergranulated, high hardness condition; Regimen C: Allopurinol 300 mg; alternative condition 2; Regimen D: Allopurinol 300 mg; alternative condition 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zyloprim® 300 mg</intervention_name>
    <arm_group_label>Zyloprim® 300 mg and three dissolution test formulations</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allopurinol 300 mg; undergranulated, high hardness condition</intervention_name>
    <description>There will be a period for interim analysis after administration of Regimen B to determine the formulation within the process design space that provides the desired in vitro dissolution variant for dosing in the subsequent study period</description>
    <arm_group_label>Zyloprim® 300 mg and three dissolution test formulations</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allopurinol 300 mg; alternative condition 2</intervention_name>
    <description>There will be a period for interim analysis after administration of Regimen C to determine the formulation within the process design space that provides the desired in vitro dissolution variant for dosing in the subsequent study period</description>
    <arm_group_label>Zyloprim® 300 mg and three dissolution test formulations</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allopurinol 300 mg; alternative condition 3</intervention_name>
    <arm_group_label>Zyloprim® 300 mg and three dissolution test formulations</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body mass index of 18.0 to 35.0 kg/m2 inclusive, or if outside the range, considered&#xD;
             not clinically significant by the Investigator. Must not exceed 40.0 kg/m2.&#xD;
&#xD;
          -  Must agree to use an adequate method of contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who test positive for the HLA-B*5801 allele.&#xD;
&#xD;
          -  Subjects who have received the last dose of an IMP (or treatment with a medical&#xD;
             device) within the previous 3 months prior to Day 1 or is currently participating in&#xD;
             another study of an IMP (or medical device).&#xD;
&#xD;
          -  History of any drug or alcohol abuse in the past 2 years.&#xD;
&#xD;
          -  Regular alcohol consumption in males &gt;21 units per week (1 unit = ½ pint beer, 25 mL&#xD;
             of 40% spirit or a 125 mL glass of wine).&#xD;
&#xD;
          -  Current smokers and those who have smoked within the last 12 months prior to&#xD;
             Screening. A breath carbon monoxide reading of greater than 10 ppm at Screening.&#xD;
&#xD;
          -  Subjects who do not have suitable veins for multiple venepunctures/cannulation as&#xD;
             assessed by the Investigator at Screening.&#xD;
&#xD;
          -  Clinically significant screening laboratory parameters (biochemistry [AST or ALT &gt; 1.5&#xD;
             × ULN], hematology or urinalysis) as judged by the Investigator (laboratory parameters&#xD;
             are listed in Appendix 1).&#xD;
&#xD;
          -  Positive drugs of abuse test result during Screening or at Admission (drugs of abuse&#xD;
             tests are listed in Appendix 1).&#xD;
&#xD;
          -  Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or&#xD;
             human immunodeficiency virus (HIV) results.&#xD;
&#xD;
          -  Subjects with rare hereditary problems of galactose intolerance, the Lapp lactase&#xD;
             deficiency or glucose-galactose malabsorption.&#xD;
&#xD;
          -  History of cardiovascular, renal, hepatic, chronic respiratory or gastrointestinal&#xD;
             disease as judged by the Investigator.&#xD;
&#xD;
          -  Evidence of renal impairment at Screening, as indicated by an estimated creatinine&#xD;
             clearance of &lt;90 mL/min using the Cockcroft-Gault equation.&#xD;
&#xD;
          -  Serious adverse reaction or serious hypersensitivity to any drug or the formulation&#xD;
             excipients.&#xD;
&#xD;
          -  Presence or history of clinically significant allergy requiring treatment, as judged&#xD;
             by the Investigator. Hayfever is allowed unless it is active.&#xD;
&#xD;
          -  Donation or loss of greater than 400 mL of blood within the previous 3 months prior to&#xD;
             Screening.&#xD;
&#xD;
          -  Subjects who are taking, or have taken, any prescribed or over-the-counter drug (other&#xD;
             than up to 4 g per day paracetamol) or herbal remedies in the 14 days before IMP&#xD;
             administration (See Section 11.4).&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chris Storgard</last_name>
    <role>Study Director</role>
    <affiliation>Ardea Biosciences, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Ruddington</city>
        <zip>NG11 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>March 20, 2015</study_first_submitted>
  <study_first_submitted_qc>March 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2015</study_first_posted>
  <last_update_submitted>December 31, 2015</last_update_submitted>
  <last_update_submitted_qc>December 31, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Allopurinol</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>May 11, 2017</submitted>
    <returned>October 4, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

